Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: Experience in six cases

European Journal of Endocrinology

Volumn 163, Issue 6, 2010, Pages 843-851

  Losa, Marco ^a   Mazza, Elena ^a   Terreni, Maria Rosa ^a   McCormack, Ann ^b   Gill, Anthony J ^c,d   Motta, Micaela ^a   Cangi, Maria Giulia ^a   Talarico, Anna ^a   Mortini, Pietro ^a   Reni, Michele ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG WITHDRAWAL; FEMALE; HORMONE DETERMINATION; HUMAN; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT RESPONSE; TUMOR VOLUME; ADENOMA; CARCINOMA; ENZYMOLOGY; HYPOPHYSIS TUMOR; METABOLISM; MIDDLE AGED;

ADENOMA; ANTINEOPLASTIC AGENTS, ALKYLATING; CARCINOMA; DACARBAZINE; FEMALE; HUMANS; MALE; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PITUITARY NEOPLASMS; PROSPECTIVE STUDIES; SALVAGE THERAPY;

EID: 78649893043     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0629     Document Type: Article

References (33)

1. Sellman WR, Laws ER, Scheithauer BW & Carpenter SM. The occurrence of dural invasion in pituitary adenomas. Journal of Neurosurgery 1986 64 402-407. (doi:10.3171/jns.1986.64.3.0402)
2. DeLellis R, Lloyd RV, Heitz P & Eng C (Eds). Tumors of Endocrine Organs (World Health Organization Classification of Tumors). Lyon: IARC Press, 2004.
3. Pernicone PJ, Scheithauer BW, Sebo TJ, Kovacs K, Horvath E, Young WF Jr, Lloyd RV, Davis DH, Guthrie BL & Schoene WC. Pituitary carcinomas: a clinicopathological study of 15 cases. Cancer 1997 79 804-812. (doi:10.1002/(SICI)1097-0142(19970215)79:4〈804::AID-CNCR18〉3.0.CO;2-3) (Pubitemid 27076347)
4. Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M & Grossman AB. Diagnosis and management of pituitary carcinomas. Journal of Clinical Endocrinology and Metabolism 2005 90 3089-3099. (doi:10.1210/jc.2004-2231)
5. Ragel BT & Couldwell WT. Pituitary carcinoma: a review of the literature. Neurosurgical Focus 2004 16 E7. (doi:10.3171/foc.2004.16.4.8)
6. Newlands ES, Stevens MFG, Wedge SR, Wheelhouse RT & Brock C. Temozolomide: a review of its discovery, chemical properties, preclinical development and clinical trials. Cancer Treatment Reviews 1997 23 35-61. (doi:10.1016/S0305-7372(97)90019-0)
7. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG & Mirimanoff RO; on behalf of the European Organization for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups ; the National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORT-NCIC trial. Lancet Oncology 2009 10 459-466. (doi:10.1016/S1470-2045(09)70025-7)
8. Agarwala SS & Kirkwood JM. Temozolomide a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 2000 5 144-151. (doi:10.1634/theoncologist.5-2- 144)
9. Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, Dunder K, Kozlovacki G, Orlefors H, Sigurd M, Oberg K, Eriksson B & Skogseid B. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clinical Cancer Research 2007 13 2986-2991. (doi:10.1158/1078-0432.CCR-06-2053)
10. Lim S, Shahinian H, Maya MM, Yong W & Heaney AP. Temozolamide: a novel treatment for pituitary carcinoma. Lancet Oncology 2006 7 518-520. (doi:10.1016/S1470-2045(06)70728-8) (Pubitemid 43796152)
11. Fadul CE, Kominsky AL, Meyer LP, Kingman LS, Kinlaw WB, Rhodes CH, Eskey CJ & Simmons NE. Long term response of pituitary carcinoma to temozolomide. Journal of Neurosurgery 2006 105 621-626. (doi:10.3171/jns.2006.105.4.621)
12. McCormack AI, McDonald KL, Gill AJ, Clark SJ, Burt MG, Campbell KA, Braund WJ, Little NS, Cook RJ, Grossman AB, Robinson BG & Clifton-Bligh RJ. Low O(6)-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clinical Endocrinology 2009 71 226-233. (doi:10.1111/j.1365-2265.2008.03487.x)
13. Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE, Horvath E & Kovacs K. Antitumor effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clinical Endocrinology 2006 65 552-553. (doi:10.1111/j.1365-2265.2006.02653.x)
14. Neff LM, Weil M, Cole A, Hedges TR, Shucart W, Lawrence D, Zhu JJ, Tischler AS & Lechan RM. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary 2007 10 81-86. (doi:10.1007/s11102-007-0014-1)
15. Losa M, Barzaghi R, Mortini P, Franzin A, Mangili F, Terreni MR & Giovanelli M. Determination of the proliferation and apoptotic index in adrenocorticotropin-secreting pituitary tumors: comparison between micro- and macroadenomas. American Journal of Pathology 2000 156 245-251.
16. Lindor NM, Burgart LJ, Leontovich O, Goldberg RM, Cunningham JM, Sargent DJ, Walsh-Vockley C, Petersen GM, Walsh MD, Leggett BA, Young JP, Barker MA, Jass JR, Hopper J, Gallinger S, Bapat B, Redston M & Thibodeau SN. Immunohistochemistry versus microsatellite instability in phenotypic colorectal tumours. Journal of Clinical Oncology 2002 20 1043-1048. (doi:10.1200/JCO.20.4. 1043)
17. Hagen C, Schroeder HD, Hansen S, Hagen C & Andersen M. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. European Journal of Endocrinology 2009 161 631-637. (doi:10.1530/EJE-09-0389)
18. Mohammed S, Kovacs K, Mason W, Smyth H & Cusimano MD. Use of temozolomide in aggressive pituitary tumors: case report. Neurosurgery 2009 64 E773-E774. (doi:10.1227/01.NEU.0000339115.12803.4E)
19. Byrne S, Karapetis C & Vrodos N. A novel use of temozolomide in a patient with malignant prolactinoma. Journal of Clinical Neuroscience 2009 16 1694-1696. (doi:10.1016/j.jocn.2009.05.013)
20. Kaltsas GA & Grossman AB. Malignant pituitary tumours. Pituitary 1998 1 69-81. (doi:10.1023/A:1009975009924)
21. Kaltsas GA, Mukherjee JJ, Plowman PN, Monson JP, Grossman AB & Besser GM. The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. Journal of Clinical Endocrinology and Metabolism 1998 83 4233-4238. (doi:10.1210/jc.83.12.4233)
22. Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, Franćois P, Jouanneau E, Passagia JG, Bernier M, Cornélius A, Figarella-Branger D, Trouillas J, Borson-Chazot F & Brue T. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French Multicenter Experience. Journal of Clinical Endocrinology and Metabolism 2010 95 4592-4599. (doi:10.1210/jc.2010-0644)
23. Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JA Jr, Vance ML, Thorner MO, Laws ER Jr & Lopes MB. Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O6-methylguanine methyltransferase (MGMT) promoter methylation and expression. Journal of Clinical Endocrinology and Metabolism 2010. (doi:10.1210/jc.2010-0441)
24. Khasraw M, Bell D & Wheeler H. Long-term use of temozolomide: could you use temozolomide for life in gliomas? Journal of Clinical Neuroscience 2009 16 854-855. (doi:10.1016/j.jocn.2008.09.005)
25. Tosoni A, Franceschi E, Ermani M, Bertorelle R, Bonaldi L, Blatt V & Brandes AA. Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. Journal of Neuro-Oncology 2008 89 179-185. (doi:10.1007/s11060-008-9600-y)
26. Wick W, Platten M & Weller M. New (alternative) temozolomide regimens for the treatment of glioma. Neuro-Oncology 2009 11 69-79. (doi:10.1215/ 15228517-2008-078)
27. Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC, Ortiz LD & Fadul CE. Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Human Pathology 2007 38 185-189. (doi:10.1016/j.humpath.2006.07.014)
28. Sheehan J, Rainey J, Nguyen J, Grimsdale R & Han S. Temozolomide-induced inhibition of pituitary adenoma cells. Journal of Neurosurgery 2010. (doi:10.3171/2010.4.JNS1024)
29. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nature Reviews. Cancer 2004 4 296-307. (doi:10.1038/nrc1319)
30. Hegi ME, Diserens AC, Gorlia Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC & Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. New England Journal of Medicine 2005 352 997-1003. (doi:10.1056/NEJMoa043331)
31. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D & Stupp R. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncology 2008 9 29-38. (doi:10.1016/S1470-2045(07)70384-4)
32. Kovacs K, Scheithauer BW, Lombardero M, McLendon RE, Syro LV, Uribe H, Ortiz LD & Penagos LC. MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathologica 2008 115 261-262. (doi:10.1007/s00401-007-0279-5)
33. Parkinson JF, Wheeler HR, Clarkson A, McKenzie CA, Biggs MT, Little NS, Cook RJ, Messina M, Robinson BG & McDonald KL. Variation of O6-methyl-guanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. Journal of Neuro- Oncology 2008 87 71-78. (doi:10.1007/s11060-007-9486-0)